Jens Huober

33.1k total citations · 4 hit papers
321 papers, 12.1k citations indexed

About

Jens Huober is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jens Huober has authored 321 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 250 papers in Oncology, 175 papers in Cancer Research and 114 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jens Huober's work include Breast Cancer Treatment Studies (149 papers), HER2/EGFR in Cancer Research (109 papers) and Cancer Treatment and Pharmacology (98 papers). Jens Huober is often cited by papers focused on Breast Cancer Treatment Studies (149 papers), HER2/EGFR in Cancer Research (109 papers) and Cancer Treatment and Pharmacology (98 papers). Jens Huober collaborates with scholars based in Germany, Switzerland and United States. Jens Huober's co-authors include Sibylle Loibl, Gϋnter von Minckwitz, Michael Untch, Christian Jackisch, Holger Eidtmann, J. Hilfrich, Jens‐Uwe Blohmer, Carsten Denkert, Peter A. Fasching and Bernd Gerber and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jens Huober

311 papers receiving 11.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

2018 516 citations Sibylle Loibl, Joyce O’Shaughnessy et al. profile →
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Jens Huober

Since Specialization

Citations

This map shows the geographic impact of Jens Huober's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Huober with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Huober more than expected).

Fields of papers citing papers by Jens Huober

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Huober. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Huober. The network helps show where Jens Huober may publish in the future.

Co-authorship network of co-authors of Jens Huober

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Huober. A scholar is included among the top collaborators of Jens Huober based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Huober. Jens Huober is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study 2024 ·npj Breast Cancer ·Matthew P. Goetz, İrfan Çiçin, Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen Johnston, Miguel Martín, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S. Rugo, Joyce O’Shaughnessy	12
2	274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study 2023 ·Annals of Oncology ·Joyce O’Shaughnessy, (unknown), Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen Johnston, M. Martín Jiménez, Priya Rastogi, Nadia Harbeck, Hope S. Rugo, Ran Wei, Valérie André, Ashwin Shahir, Matthew P. Goetz	1
3	Enhancing coping skills through brief interventions during cancer therapy – a quasi-experimental clinical pilot study 2023 ·Frontiers in Psychology ·(unknown), (unknown), Marc N. Jarczok, (unknown), (unknown), Regine Mayer‐Steinacker, Jens Huober, Harald Gündel, Klaus Hönig	1
4	LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes 2023 ·Annals of Oncology ·Nadia Harbeck, Priya Rastogi, J. O’Shaughnessy, Frances Boyle, Javier Cortés, Hope S. Rugo, Matthew P. Goetz, Erika Hamilton, Chiun‐Sheng Huang, Elżbieta Senkus, A. Tryakin, Patrick Neven, Jens Huober, Ran Wei, Valérie André, (unknown), Belén San Antonio, Ashwin Shahir, M. Martín Jiménez, Stephen Johnston	11
5	Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial 2023 ·European Journal of Cancer ·Marcus Schmidt, Ulrike Nitz, Toralf Reimer, Sabine Schmatloch, Heiko Graf, Marianne Just, Elmar Stickeler, Michael Untch, Ingo B. Runnebaum, Antje Belau, Jens Huober, Christian Jackisch, Manfred Hofmann, (unknown), Valentina Nekljudova, Sibylle Loibl	1
6	Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial 2023 ·Clinical Cancer Research ·Hans Wildiers, Anne Armstrong, Eveline Cuypere, Florence Dalenc, Luc Dirix, (unknown), Frederik Marmé, Carolina P. Schröder, Jens Huober, François P. Duhoux, Peter Vuylsteke, Agnes Jager, Étienne Brain, (unknown), Zsuzsanna Pápai, C. Willemien Menke‐van der Houven van Oordt, (unknown), (unknown), Chrystelle Brignone, Frédéric Triebel	12
7	Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial 2022 ·Journal of Clinical Oncology ·Jens Huober, Carlos H. Barrios, Naoki Niikura, Michał Jarząb, Yuan‐Ching Chang, (unknown), José Luiz Pedrini, Lyudmila Zhukova, Vilma Graupner, Daniel Eiger, Volkmar Henschel, (unknown), Chiara Lambertini, Eleonora Restuccia, Hong Zhang, (unknown)	82
8	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups 2021 ·npj Breast Cancer ·Stephen Johnston, Joyce O’Shaughnessy, Miguel Martín, Jens Huober, Masakazu Toi, Joohyuk Sohn, Valérie André, Holly Martin, Molly Catherine Hardebeck, Matthew P. Goetz	36
9	Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial 2020 ·Breast Cancer Research ·Serena Di Cosimo, Luca Porcu, Dominique Agbor‐Tarh, Saverio Cinieri, Maria Alice Franzoi, Maria Carmen De Santis, Cristina Saura, Jens Huober, Debora Fumagalli, Miguel Izquierdo, Martine Piccart, Maria Grazia Daidone, Evandro de Azambuja	22
10	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor 2018 ·Clinical Cancer Research ·Sibylle Loibl, Karsten E. Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit M. Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb‐Esfahani, Volkmar Müller, Annette Staebler, Gϋnter von Minckwitz, Ralf Kronenwett, Carsten Denkert	8
11	Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) 2018 ·Journal of Clinical Oncology ·Michael Untch, Gϋnter von Minckwitz, Bernd Gerber, Christian Schem, Mahdi Rezai, Peter A. Fasching, Hans Tesch, Holm Eggemann, Claus Hanusch, Jens Huober, Christine Solbach, Christian Jackisch, Georg Kunz, Jens‐Uwe Blohmer, Maik Hauschild, Tanja Fehm, Valentina Nekljudova, Sibylle Loibl, (unknown)	40
12	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial 2017 ·Clinical Cancer Research ·Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, J. Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gϋnter von Minckwitz, Michael Untch, Klaus Pantel	82
13	Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) 2017 ·European Journal of Cancer ·Sherko Kümmel, Stefan Paepke, Jens Huober, Christian Schem, Michael Untch, Jens‐Uwe Blohmer, W. Eiermann, Bernd Gerber, Claus Hanusch, J. Hilfrich, Christian Jackisch, Andreas Schneeweiß, Carsten Denkert, Knut Engels, Peter Klare, Peter A. Fasching, Gϋnter von Minckwitz, Nicole Burchardi, Sibylle Loibl	17
14	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer breakdown → 2017 ·Journal of Clinical Oncology ·Matthew P. Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch–Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin‐Cheh Chen, Luís Manso, Orit Freedman, Georgina Garnica Jaliffe, Tammy Forrester, Martin Frenzel, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Angelo Di Leo	1125
15	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer 2016 ·Clinical Cancer Research ·Sibylle Loibl, Silvia Darb‐Esfahani, Jens Huober, Alexander C. Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit M. Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gϋnter von Minckwitz, Michael Untch, Carsten Denkert	34
16	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna Samant, Steve Olsen, Sanne Lysbet de Haas, Mark D. Pegram	150
17	Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study 2014 ·Clinical Cancer Research ·Frederick Klauschen, Stephan Wienert, Wolfgang Schmitt, Sibylle Loibl, Bernd Gerber, Jens‐Uwe Blohmer, Jens Huober, Thomas Rüdiger, E Erbstösser, Keyur Mehta, Bianca Lederer, Manfred Dietel, Carsten Denkert, Gϋnter von Minckwitz	78
18	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer 2013 ·Journal of Clinical Oncology ·Gϋnter von Minckwitz, Jens‐Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, W. Eiermann, Bernd Gerber, Claus Hanusch, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Sherko Kümmel, Stefan Paepke, Andreas Schneeweiß, Michael Untch, Dirk M. Zahm, Keyur Mehta, Sibylle Loibl	265
19	Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study 2010 ·Journal of Clinical Oncology ·Volker Moebus, Christian Jackisch, Hans-Joachim Lueck, Andreas du Bois, Christoph Thomssen, Christian M. Kurbacher, Walther Kuhn, Ulrike Nitz, Andreas Schneeweiß, Jens Huober, Nadia Harbeck, Gϋnter von Minckwitz, Ingo B. Runnebaum, Axel Hinke, R. Kreienberg, Gottfried E. Konecny, Michael Untch	126
20	Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study 2010 ·Breast Cancer Research and Treatment ·Jens Huober, (unknown), Carsten Denkert, Hans Tesch, Erich Weiß, Dirk M. Zahm, Antje Belau, F Khandan, Maik Hauschild, Christoph Thomssen, B. Högel, Silvia Darb‐Esfahani, Keyur Mehta, Sibylle Loibl	220

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact